3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
2
Breast Neoplasms
2
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
19
Letrozole
8
Anastrozole
6
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Injections
4
Goserelin
4
Docetaxel
4
pyrotinib
3
exemestane
3
trastuzumab deruxtecan
2
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
abemaciclib
2
Vinorelbine
2
Trastuzumab
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Aromatase Inhibitors
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
vandetanib
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Breast Cancer
×
balixafortide
×
Clear all
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn